Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

MNG182

81f13d33-a7d8-534d-839f-ab1fe72fd6e3

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.412
  • G2M_CHECKPOINT+0.395
  • MITOTIC_SPINDLE+0.265
  • MYC_TARGETS_V1+0.255
  • SPERMATOGENESIS+0.232
  • INTERFERON_ALPHA_RESPONSE+0.096
  • UV_RESPONSE_DN+0.094
  • MYC_TARGETS_V2+0.069
  • PEROXISOME+0.021
  • FATTY_ACID_METABOLISM+0.013

Top 10 suppressed

  • TNFA_SIGNALING_VIA_NFKB-0.447
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.436
  • WNT_BETA_CATENIN_SIGNALING-0.404
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.398
  • APOPTOSIS-0.386
  • TGF_BETA_SIGNALING-0.374
  • CHOLESTEROL_HOMEOSTASIS-0.344
  • P53_PATHWAY-0.339
  • HYPOXIA-0.307
  • IL2_STAT5_SIGNALING-0.281

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SAMN03290905
melanoma-umap@29
0.861
2C3N-02728
lung-landscapes@6
cohortMD10.859
3SAMN03290898
melanoma-umap@29
0.847
4R160
bladder-landscape@3
0.840
5TCGA-BB-4223-01A-01R-1436-07
head-neck@1
0.836
6SRR934790
brain-umap@2
0.833
7BS_YEW22W35
brain-umap@2
high-grade glioma0.832
8SRR12202476
bladder-landscape@3
0.825
9SRR975551
colon-landscapes@1
0.822
10BS_7FWZ518S
brain-umap@2
medulloblastoma0.821

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 11 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.412Inavolisib— uncovered
G2M_CHECKPOINT0.395Inavolisib— uncovered
MITOTIC_SPINDLE0.265Inavolisib— uncovered
MYC_TARGETS_V10.255Inavolisib— uncovered
SPERMATOGENESIS0.232Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.096Inavolisib— uncovered
UV_RESPONSE_DN0.094Inavolisib— uncovered
MYC_TARGETS_V20.069Idelalisib— uncovered
PEROXISOME0.021Idelalisib— uncovered
FATTY_ACID_METABOLISM0.013Inavolisib— uncovered
KRAS_SIGNALING_DN0.004Remibrutinib— uncovered